Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
October 20, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on...
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
October 13, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expanded Access to EXPAREL for Patients Undergoing Oral and Maxillofacial Procedures
September 27, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sevāredent Sourcing Solutions, a Group Purchasing Organization (GPO) that creates a competitive advantage for like-minded dental organizations through...
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy
September 21, 2022 08:00 ET
|
Pacira BioSciences
-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- --...
Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older
September 20, 2022 08:00 ET
|
Pacira BioSciences
TAMPA, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the leading global provider of non-opioid pain management options, announced that the European Medicines...
Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022
September 13, 2022 08:00 ET
|
Pacira BioSciences
-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 – -- More than 11 million patients have received EXPAREL since launch -- TAMPA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE)...
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty
September 07, 2022 07:00 ET
|
Pacira BioSciences
TAMPA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022
August 10, 2022 08:00 ET
|
Pacira BioSciences
-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 -- TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its...
NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communities About Non-Opioid Options to Manage Pain
August 09, 2022 07:30 ET
|
Pacira BioSciences
TAMPA, Fla. and MOUNT LAUREL, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- The National Football League Alumni Association (NFLA), the oldest, most well-known and well-respected retired player...
Pacira BioSciences Reports Second Quarter 2022 Financial Results
August 03, 2022 08:00 ET
|
Pacira BioSciences
-- Second quarter revenue of $169 million, increased 25% over prior year, demonstrating successful integration and synergies from Flexion acquisition –-- Strong topline performance delivers solid net...